Diabetic Retinopathy - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 157 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Diabetic Retinopathy - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Diabetic Retinopathy - Pipeline Review, H2 2014', provides an overview of the Diabetic Retinopathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diabetic Retinopathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diabetic Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Retinopathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Diabetic Retinopathy Overview 11
Therapeutics Development 12
Pipeline Products for Diabetic Retinopathy - Overview 12
Pipeline Products for Diabetic Retinopathy - Comparative Analysis 13
Diabetic Retinopathy - Therapeutics under Development by Companies 14
Diabetic Retinopathy - Therapeutics under Investigation by Universities/Institutes 17
Diabetic Retinopathy - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Diabetic Retinopathy - Products under Development by Companies 21
Diabetic Retinopathy - Products under Investigation by Universities/Institutes 22
Diabetic Retinopathy - Companies Involved in Therapeutics Development 23
Kowa Company, Ltd. 23
Antisense Therapeutics Limited 24
BioDiem Ltd 25
Regeneron Pharmaceuticals, Inc. 26
R-Tech Ueno, Ltd. 27
Paloma Pharmaceuticals, Inc. 28
Acucela Inc. 29
Gene Signal International SA 30
Promedior, Inc. 31
Inotek Pharmaceuticals Corporation 32
Angstrom Pharmaceuticals, Inc. 33
Stemedica Cell Technologies, Inc. 34
Dimerix Bioscience Pty Ltd 35
Resolvyx Pharmaceuticals, Inc 36
Charlesson LLC. 37
MacuCLEAR, Inc. 38
Stelic Institute & Co. 39
EyeCyte, Inc. 40
Vascular Pharmaceuticals, Inc. 41
PanOptica, Inc. 42
EyeGene, Inc. 43
Targazyme, Inc. 44
Aprogen, Inc. 45
MingSight Pharmaceuticals 46
Bionure Farma, S.L. 47
Islet Sciences, Inc. 48
Foresee Pharmaceuticals, LLC 49
Biomar Microbial Technologies 50
Diabetic Retinopathy - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Target 52
Assessment by Mechanism of Action 55
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
aflibercept (recombinant) - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ripasudil - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
AKB-9778 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ATL-1103 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
DG-3173 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
emixustat hydrochloride - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
aganirsen - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
GLY-230 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
EG-Mirotin - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
DT-23552 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
RX-20001 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
A-6 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
P-529 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
BDM-E - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
RTU-007 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Mesenchymal Stem Cells - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
PRM-167 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
A-717 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
MS-553 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
PAN-90806 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
MC-4001 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
AP-202 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
FP-002 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Recombinant Protein for Cancer and Diabetic Retinopathy - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Cyndacel-M - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
VPI-2690-B - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Small Molecule for Diabetic Neuropathy and Retinopathy - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
TZ-101 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
V-1932 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
EC-301 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Adenomatosis Polyposis Coli Down-Regulated 1 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Stem Cell Therapy for Diabetic Retinopathy - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
STNM-1510 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
IB-09A0133 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
CLT-01007 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
CLT-01001 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
CLT-01012 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Recombinant Proteins to Activate EGFR for Metabolic Disorders and Ophthalmology - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
BN-201 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
EC-200 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
DMX-200 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
E-1086 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Diabetic Retinopathy - Recent Pipeline Updates 122
Diabetic Retinopathy - Dormant Projects 145
Diabetic Retinopathy - Discontinued Products 146
Diabetic Retinopathy - Product Development Milestones 147
Featured News & Press Releases 147
Aug 08, 2014: Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic Retinopathy 147
Apr 14, 2014: ThromboGenics provides update on JETREA 147
Feb 20, 2014: Positive Case Report on Ohr Pharmaceutical's Squalamine Presented at the 37th Annual Macula Society Meeting 148
Jun 03, 2013: Oxford BioMedic Voluntarily Pauses Recruitment Into Phase I Study Of RetinoStat 149
May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 149
May 01, 2012: Promedior To Present Data From Preclinical Studies Of Pentraxin-2 At ARVO Annual Meeting 150
May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 151
Apr 27, 2012: Ampio Receives US And Canadian Notice Of Allowance Of Patents For Optina 151
Mar 19, 2012: Ampio Announces Positive Preliminary Update On Optina Clinical Trial To Treat Diabetic Macular Edema 152
Feb 09, 2012: Antisense Therapeutics Provides Development Update On ATL1103 153
Appendix 156
Methodology 156
Coverage 156
Secondary Research 156
Primary Research 156
Expert Panel Validation 156
Contact Us 157
Disclaimer 157

List of Tables
Number of Products under Development for Diabetic Retinopathy, H2 2014 12
Number of Products under Development for Diabetic Retinopathy - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Late Stage Development, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Investigation by Universities/Institutes, H2 2014 22
Diabetic Retinopathy - Pipeline by Kowa Company, Ltd., H2 2014 23
Diabetic Retinopathy - Pipeline by Antisense Therapeutics Limited, H2 2014 24
Diabetic Retinopathy - Pipeline by BioDiem Ltd, H2 2014 25
Diabetic Retinopathy - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 26
Diabetic Retinopathy - Pipeline by R-Tech Ueno, Ltd., H2 2014 27
Diabetic Retinopathy - Pipeline by Paloma Pharmaceuticals, Inc., H2 2014 28
Diabetic Retinopathy - Pipeline by Acucela Inc., H2 2014 29
Diabetic Retinopathy - Pipeline by Gene Signal International SA, H2 2014 30
Diabetic Retinopathy - Pipeline by Promedior, Inc., H2 2014 31
Diabetic Retinopathy - Pipeline by Inotek Pharmaceuticals Corporation, H2 2014 32
Diabetic Retinopathy - Pipeline by Angstrom Pharmaceuticals, Inc., H2 2014 33
Diabetic Retinopathy - Pipeline by Stemedica Cell Technologies, Inc., H2 2014 34
Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2014 35
Diabetic Retinopathy - Pipeline by Resolvyx Pharmaceuticals, Inc, H2 2014 36
Diabetic Retinopathy - Pipeline by Charlesson LLC., H2 2014 37
Diabetic Retinopathy - Pipeline by MacuCLEAR, Inc., H2 2014 38
Diabetic Retinopathy - Pipeline by Stelic Institute & Co., H2 2014 39
Diabetic Retinopathy - Pipeline by EyeCyte, Inc., H2 2014 40
Diabetic Retinopathy - Pipeline by Vascular Pharmaceuticals, Inc., H2 2014 41
Diabetic Retinopathy - Pipeline by PanOptica, Inc., H2 2014 42
Diabetic Retinopathy - Pipeline by EyeGene, Inc., H2 2014 43
Diabetic Retinopathy - Pipeline by Targazyme, Inc., H2 2014 44
Diabetic Retinopathy - Pipeline by Aprogen, Inc., H2 2014 45
Diabetic Retinopathy - Pipeline by MingSight Pharmaceuticals, H2 2014 46
Diabetic Retinopathy - Pipeline by Bionure Farma, S.L., H2 2014 47
Diabetic Retinopathy - Pipeline by Islet Sciences, Inc., H2 2014 48
Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals, LLC, H2 2014 49
Diabetic Retinopathy - Pipeline by Biomar Microbial Technologies, H2 2014 50
Assessment by Monotherapy Products, H2 2014 51
Number of Products by Stage and Target, H2 2014 54
Number of Products by Stage and Mechanism of Action, H2 2014 57
Number of Products by Stage and Route of Administration, H2 2014 59
Number of Products by Stage and Molecule Type, H2 2014 61
Diabetic Retinopathy Therapeutics - Recent Pipeline Updates, H2 2014 122
Diabetic Retinopathy - Dormant Projects, H2 2014 145
Diabetic Retinopathy - Discontinued Products, H2 2014 146